Effects of a combined oral contraceptive containing 20 mcg of ethinylestradiol and 3 mg of drospirenone on the blood pressure, renin-angiotensin-aldosterone system, insulin resistance, and androgenic profile of healthy young women

Gynecological Endocrinology

Volumn 31, Issue 11, 2015, Pages 912-915

  Giribela, Cassiana Rosa Galvão ^a   Consolim Colombo, Fernanda Marciano ^a   Nisenbaum, Marcelo Gil ^a   Moraes, Tercio Lemos De ^a   Giribela, Aricia Helena Galvão ^a   Baracat, Edmund Chada ^a   Melo, Nilson Roberto De ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Blood pressure; drospirenone; lipids; metabolism; oral contraceptive

Indexed keywords

ALDOSTERONE; ANDROGEN; ANDROSTENEDIONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRASTERONE SULFATE; TESTOSTERONE; TRIACYLGLYCEROL; ANDROSTANE DERIVATIVE; CHOLESTEROL; DROSPIRENONE; DRUG COMBINATION; ESTROGEN; ETHINYLESTRADIOL; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; RENIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HORMONE ACTION; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; BODY MASS; CASE CONTROL STUDY; DRUG COMBINATION; DRUG EFFECTS;

ADULT; ALDOSTERONE; ANDROSTENEDIONE; ANDROSTENES; BLOOD PRESSURE; BODY MASS INDEX; CASE-CONTROL STUDIES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CONTRACEPTIVES, ORAL, COMBINED; DEHYDROEPIANDROSTERONE SULFATE; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INSULIN RESISTANCE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RENIN; RENIN-ANGIOTENSIN SYSTEM; TESTOSTERONE; TRIGLYCERIDES;

EID: 84949464198     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2015.1062860     Document Type: Article

References (30)

1. Mishell Jr DR. State of the art in hormonal contraception: an overview. Am J Obstet Gynecol 2004; 190: S1-4
2. Sitruk-Ware R, Nath A. Metabolic effects of contraceptive steroids. Rev Endocr Metab Disord 2011; 12: 63-75
3. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 12: 169-78
4. Nath A, Sitruk-Ware R. Different cardiovascular effects of progestins according to structure and activity. Climacteric 2009; 12: 96-101
5. Godsland IF, Walton C, Felton C, et al. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992; 74: 64-70
6. Kojima T, Lindheim SR, Duffy DM, et al. Insulin sensitivity is decreased in normal women by doses of ethinyl estradiol used in oral contraceptives. Am J Obstet Gynecol 1993; 169: 1540-4
7. Weir RJ. When the pill causes a rise in blood pressure. Drugs 1978; 16: 522-7
8. Crane MG, Harris JJ. Estrogens and hypertension: effect of discontinuing estrogens on blood pressure, exchangeable sodium and the renin-aldosterone system. Am J Med Sci 1978; 276: 33-55
9. The WHO multicentre trial of the vasopressor effects of combined oral contraceptives: 1. Comparisons with IUDs. Contraception 1989; 40: 129-45. 33
10. The WHO multicentre trial of the vasopressor effects of combined oral contraceptives: 2. Lack of effect of estrogen. Contraception 1989; 40: 147-56. 34
11. Chasan-Taber L, Walter CW, JoAnn EM, et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 1996; 94: 483-9
12. Oelkers W, Schoneshofer M, Blumel A. Effects of progesterone and four synthetic progestogens on sodium balance and the renin-aldosterone system in man. J Clin Endocrinol Metab 1974; 39: 882-90
13. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996; 61: 166-71
14. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care 2002; 7: 19-26
15. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 1991; 73: 837-42
16. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R. Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 476-8
17. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 1816-21
18. World Health Organization. Medical eligibility criteria for contraceptive use. 4th ed. Amsterdam: Elsevier; 2010
19. Pickering TG, Hall JE, Appel LJ, et al. AHA Scientific Statement. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research. Hypertension 2005; 45: 142-61
20. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811-19
21. Giribela CR, Melo NR, Silva RC, et al. A combined oral contraceptive containing drospirenone changes neither endothelial function nor hemodynamic parameters in healthy young women: a prospective clinical trial. Contraception 2012; 86: 35-41
22. Nisenbaum MG, de Melo NR, Giribela CR, et al. Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial. Eur J Obstet Gynecol Reprod Biol 2014; 175: 62-6
23. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005; 71: 409-16
24. Taneepanichskul S, Phupong V. Influence of a new oral contraceptive with drospirenone on lipid metabolism. Gynecol Endocrinol 2007; 23: 347-50
25. Gaspard U, Endrikat J, Desager JP, et al. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles. Contraception 2004; 69: 271-8
26. Cagnacci A, Piacenti I, Zanin R, et al. Influence of an oral contraceptive containing drospirenone on insulin sensitivity of healthy women. Eur J Obstet Gynecol Reprod Biol 2014; 178: 48-50
27. Oelkers W, Foidart JM, Dombrovicz N, et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 1995; 80: 18:16-21
28. Cagnacci A, Ferrari S, Tirelli A, et al. Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. Contraception 2009; 79: 111-16
29. Knopp RH, Broyles FE, Cheung M, et al. Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception 2001; 63: 1-11
30. Song S, Chen JK, Yang PJ, et al. A cross-over study of three oral contraceptives containing ethinyloestradiol and either desogestrel or levonorgestrel. Contraception 1992; 45: 523-32